MRI scans are strong diagnostics with high-definition images of what lies inside a body. Strong magnetic fields require precaution, as brought out by an instance where a young woman suffered very serious injuries due to an oversight in a metallic core within a silicone sex toy that she happened to have before the MRI scan. This makes a stark reminder about the potentially deadly consequences of missing metal objects when such procedures are being performed. In April 2023, a 23-year-old woman went into an MRI with a silicone plug containing a metal core that was not known.
She thought that the item is made entirely out of silicone according to the advertising. However, the strong magnetic field of the MRI machine interacted with the hidden metal, dragging the object through her body and causing excruciating pain. According to reports from the U.S. Food and Drug Administration (FDA), the scene was harrowing, with the woman screaming in agony and requiring immediate hospitalization. Despite pre-scan screenings, which are routine prior to a scan, the patient did not inform the facility that the object existed because he presumed it was purely non-metallic. This caused serious injuries that led to the patient's law suit against the manufacturer for deceitful misrepresentations of material content.
MRI machines employ magnets between 0.5 to 3 Tesla (T). This is thousands of times stronger than the Earth's magnetic field. The tremendous force causes ferromagnetic materials, like iron and nickel, to be magnetized quickly and become strongly attracted toward the magnet. Objects as small as hairpins or paper clips will accelerate at 40 miles per hour inside the magnetic field.
The force can lead to catastrophic injuries in items lodged within the body, such as metallic implants or foreign objects. Metallic cores within devices, like pacemakers or intrauterine devices, must be disclosed to radiologists to prevent such complications.
On these claims, Dr. Adam Taylor, a specialist in human anatomy, weighed his words in a international health website and added that the distance away and mass of this object would increase its velocity towards that of sound, "The acceleration would be phenomenal, but with a metallic core, it can't go anywhere near supersonic speeds. As for the size, the magnetic acceleration to the internal soft tissues would ensure that there could be severe intracranial trauma."
The injuries inflicted in this case likely involved damage to major blood vessels, nerves, or organs, highlighting the devastating impact of even minor oversight during an MRI scan.
This is not an isolated case. There are documented cases of metallic objects causing serious damage during MRI scans with a 65-year-old man with schizophrenia swallowed metal objects, including sockets and a hinge pin. The powerful magnetic field during an MRI scan caused the objects to rupture his stomach, resulting in serious injuries.
A toddler who ingested 11 small magnets perforated his bowel while undergoing a scan, making his case unique. In another deadly but extremely rare incident, there have been people who hide a firearm on themselves during MRI procedures. Magnetic attraction can trigger a discharge in a weapon and has led to some fatal injuries.
These cases emphasize the very strong need for adequate screening and patient education prior to an MRI.
Medical professionals have been trained to avoid risks. This is by properly screening a patient for metallic objects. In general, most pre-scan protocols include:
The case emphasizes the importance of product labeling by manufacturers, especially those products that are likely to unintentionally cause harm to health. The patient's assumption that her device was 100% silicone points to a larger problem in consumer markets with misinformation.
It also reminds the patients to report any possible dangers to the medical professionals, no matter how the objects look non-metallic. In sensitive cases, patients can request private discussions with healthcare providers to ensure safety without discomfort.
In the end, it is a joint effort from manufacturers, healthcare professionals, and patients that can prevent such tragedies. Manufacturers must ensure truthful marketing, while healthcare providers should educate patients about the dangers of metal objects in MRI settings. For patients, understanding the risks and actively participating in pre-scan disclosures can be lifesaving.
This young woman's experience is a sobering example of the unforeseen dangers posed by MRI machines when precautions are overlooked. It serves as a wake-up call to address gaps in patient awareness, medical protocols, and product transparency. By learning from this incident, the medical community and the public can work together to ensure MRI scans remain a safe and effective diagnostic tool.
Credit: AI
A newly identified brain protein may help slow the progression of Alzheimer's disease, according to new research that sheds light on how the disease spreads through the brain.
Scientists have found that a protein called SORLA acts as a natural defense against the toxic tau protein, limiting the brain damage that causes memory loss and cognitive decline.
The findings, published in Nature Neuroscience, suggest that boosting SORLA activity could become a therapeutic strategy.
The study found that SORLA regulates how tau proteins move between neurons. While amyloid plaques have long dominated Alzheimer's research, mounting evidence suggests that the spread of tau in the brain is more closely linked to the symptoms of Alzheimer's.
When SORLA levels were low, toxic tau spread more easily from one brain cell to another. In contrast, increasing SORLA significantly reduced tau accumulation, protected brain tissue from shrinking, and preserved memory in mouse models of Alzheimer's disease.
"Our findings identify SORLA as a potent endogenous suppressor of tau propagation," the researchers wrote, adding that enhancing SORLA function "could represent a promising therapeutic strategy for limiting the progression of Alzheimer's disease."
Also read: Alzheimer's Drug Leqembi Helps Over 75% Of Patients Remain Stable Or Improve: Real-World Study
Current Alzheimer's drugs like Leqembi primarily target amyloid-beta plaques. Although these treatments can slow disease progression in some patients, they do not directly stop the spread of tau, which drives the loss of brain cells which worsens dementia.
The discovery of SORLA offers a different approach by targeting one of the disease's most dangerous aspects: tau propagation.
The SORLA findings were demonstrated primarily in laboratory models, meaning much more research is needed before therapies can be tested in people.
However, researchers say identifying the brain's own protective mechanisms provides an important roadmap for developing treatments that not only remove harmful proteins but also prevent them from spreading.
If future studies confirm these findings in humans, therapies that boost SORLA could potentially be combined with existing anti-amyloid medicines to slow Alzheimer's progression more effectively.
The SORLA discovery comes amid growing momentum in tau-based Alzheimer's research.
Just this month, researchers reported encouraging results from diranersen, an experimental therapy designed to reduce production of the tau protein itself.
In a mid-stage clinical trial involving around 400 people with early Alzheimer's disease, the drug lowered tau levels and showed signs of slowing cognitive decline in some participants, although larger studies are needed to confirm its effectiveness.
Also read: Excessive TV Watching In Midlife May Shrink Brain Areas Essential For Memory, Study Finds
SORLA (Sorting Protein-Related Receptor with LDLR Class A Repeats) is a receptor protein naturally present in brain cells.
Scientists have known for years that low SORLA levels are associated with an increased risk of Alzheimer's disease because the protein helps process amyloid precursor protein.
Tau is a normal protein that helps stabilize the internal structure of nerve cells. In Alzheimer's disease, however, tau becomes abnormally folded and forms neurofibrillary tangles.
These tangles spread through interconnected brain regions, disrupting communication between neurons, and eventually causing them to die.
Researchers believe the progression of tau pathology closely mirrors the progression of memory loss and cognitive impairment seen in Alzheimer's patients.
Credit: AI generated image
Women with polyendocrine metabolic ovarian syndrome (PMOS)—formerly known as polycystic ovarian syndrome (PCOS)—face a significantly higher risk of heart attacks, strokes, and other cardiovascular diseases, according to a large study published in The Lancet Obstetrics, Gynaecology & Women's Health.
PMOS affects an estimated 10–13% of women of reproductive age. Researchers analyzed data from more than 2 million women and found that those with PMOS had a substantially higher risk of serious cardiovascular events, even after accounting for established risk factors such as obesity, diabetes, high blood pressure, smoking, and high cholesterol.
The findings, by researchers from the University of Pennsylvania and the University of Rochester, suggest that PMOS should be recognized not only as a reproductive health condition but also as a major cardiometabolic disorder, underscoring the need for routine cardiovascular monitoring in affected women.
Also read: PCOS Is Now PMOS: What The Name Change Means For Millions Of Women
Women with PMOS were significantly more likely to develop atherosclerotic cardiovascular disease (ASCVD), including heart attacks and strokes.
After adjusting for traditional cardiovascular risk factors, researchers found that women with PMOS were:
"Our work shows that it is imperative for clinicians to closely track and evaluate cardiovascular health in patients with PMOS," said Dr. Anuja Dokras, senior author of the study and Founders Professor of Women's Health at the University of Pennsylvania.
She advised women with PMOS to lower their cardiovascular risk by:
PMOS is the new name for PCOS, adopted following an international consensus announced in May 2026 by the World Health Organization, the Endocrine Society, and other leading organizations.
The new name reflects the understanding that the condition affects multiple body systems—not just the ovaries. PMOS is a complex hormonal and metabolic disorder linked to an increased risk of:
The condition can affect:
Experts said the term PCOS was misleading because many patients believed it referred to ovarian cysts, whereas the condition is characterized by increased ovarian follicles rather than true cysts.
"My patients often assumed they had cysts on their ovaries, but instead, people with PMOS have increased follicles that can resemble cysts," said Dr. Dokras. "The effects of PMOS extend far beyond gynecologic health. The new name better reflects the multiple hormonal and metabolic systems involved and encourages more comprehensive care."
The new name aims to explain the condition more accurately and comprehensively.
Credit: Instagram
Former England forward and manager Kevin Keegan has died after battling stage 4 stomach cancer. He was 75.
Keegan died surrounded by his wife, Jean, and their daughters.
"It is with immense sadness that we announce that Kevin Keegan has passed away at the age of 75," a statement from Keegan's family read.
"The former England player and manager had been battling cancer and was surrounded by his wife and daughters in his final moments.
"Kevin, a double Ballon d'Or winner, was a much-loved husband, father and grandfather. The family would like to thank Kevin's incredible medical team for all their support. This is a hugely difficult time and they are requesting space and privacy."
Earlier this year, his family announced that the former England captain had been diagnosed with stage 4 cancer and was preparing to begin treatment. In June, Keegan revealed that the disease had spread to other parts of his body.
Known affectionately as "King Kev," Keegan spoke openly about his diagnosis during a public appearance in Newcastle, reflecting on his health with his trademark honesty and humor. Fans listened in silence as he shared his journey through the illness.
His death has prompted tributes from football fans around the world.
Also read: Cancer Kills Over 26,000 Daily; Cases to Hit 35 Million by 2050, Says WHO Report
Born in Armthorpe, Doncaster, on February 14, 1951, Keegan began his senior career with Scunthorpe United before joining Liverpool in 1972. He later played for Hamburger SV, Southampton and Newcastle United, ending his playing career with Blacktown City in Australia.
During a club career spanning 592 appearances, Keegan scored 204 goals. He also earned 63 caps for England, scoring 21 goals.
As a manager, Keegan had two spells at Newcastle United and also managed Fulham, England and Manchester City. He guided England to UEFA Euro 2000 through a play-off victory over Scotland before resigning later that year after a disappointing start to the tournament.
Read More: Don't Ignore These Cancer Symptoms: Oncologist Shares The Early Warning Signs
Stomach cancer, also known as gastric cancer, develops in the lining of the stomach. It is more common in older adults than in younger people. According to the American Cancer Society, about six in 10 people diagnosed with stomach cancer each year are aged 65 or older. The lifetime risk is also higher in men (about 1 in 101) than in women (about 1 in 155).
Scientists from the International Agency for Research on Cancer (IARC), part of the World Health Organization (WHO), estimate that infection with the common stomach bacterium Helicobacter pylori (H. pylori) causes 76% of stomach cancer cases globally. The infection often produces no obvious symptoms beyond common digestive complaints, allowing it to go undetected for years.
Doctors advise seeking medical attention if symptoms such as persistent indigestion, nausea, unexplained weight loss, loss of appetite, or upper abdominal discomfort last for more than three weeks.
Around 18 people in the UK and 83 people in the US are diagnosed with stomach cancer every day. Because the disease is often detected at an advanced stage, treatment can be challenging. In the UK, only about 17% of patients survive beyond 10 years after diagnosis.
H. pylori infection can be detected through simple tests and treated with antibiotics. Early diagnosis and treatment can significantly reduce the risk of stomach cancer. Health experts stress that recognizing persistent digestive symptoms and seeking timely medical care can save lives.
© 2024 Bennett, Coleman & Company Limited